An open-label, single centre dose-escalation phase I trial of AEOL-10150 in healthy volunteers.

Trial Profile

An open-label, single centre dose-escalation phase I trial of AEOL-10150 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs AEOL 10150 (Primary)
  • Indications Acute radiation syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Mar 2017 According to an Aeolus Pharmaceuticals Inc media release, first 6 patients have completed dosing. A total of 9 patients will receive a single injection during this study, which is scheduled to be completed during the 2nd quarter of 2017
    • 22 Feb 2017 According to an Aeolus Pharmaceuticals Inc media release, the data from this study will be included in the Company's pre-Emergency Use Authorization application in Lung-ARS and will also be used to support the IPF and radiation therapy indications, as well as the use of AEOL 10150 as a medical countermeasure against lung damage from exposure to sulfur mustard gas.
    • 22 Feb 2017 Status changed from planning to recruiting, according to an Aeolus Pharmaceuticals Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top